title: Suppressive effects of britanin, a sesquiterpene compound isolated from Inulae flos, on mast cell-mediated inflammatory responses.
abstract: Mast cells are central players in immediate-type hypersensitvity and inflammatory responses. In the present study, the effects of britanin on the passive cutaneous anaphylaxis (PCA) reaction in mice and on the phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI)-induced production of pro-inflammatory cytokines in human mast cell line (HMC-1) were evaluated. The oral administration of britanin (10-20 mg/kg) decreased the mast cell-mediated PCA reaction in IgE-sensitized mice. In the activity and mechanism of britanin in vitro assay, britanin suppressed the gene expression and secretion of pro-inflammatory cytokines in a dose-dependent manner in HMC-1. In addition, britanin attenuated PMACI-induced activation of NF-κB as indicated by the inhibition of the degradation of IκBα, nuclear translocation of NF-κB, NF-κB/DNA binding activity assay, and blocked the phosphorylation of p38 MAP kinase, in a dose-dependent manner. We conclude that britanin may have potential as a treatment for allergic-inflammatory diseases.
authors.affiliation: Research and Development Division, Korean Promotion Institute for Traditional Medicine Industry, Gyeongsan 710-210, Republic of Korea.
authors.forename: Hyo-Hyun
authors.initials: HH
authors.lastname: Park
authors.forename: Sun-Gun
authors.initials: SG
authors.lastname: Kim
authors.forename: Young Na
authors.initials: YN
authors.lastname: Park
authors.forename: Jiean
authors.initials: J
authors.lastname: Lee
authors.forename: Youn Ju
authors.initials: YJ
authors.lastname: Lee
authors.forename: Na-Young
authors.initials: NY
authors.lastname: Park
authors.forename: Kyu-Tae
authors.initials: KT
authors.lastname: Jeong
authors.forename: Eunkyung
authors.initials: E
authors.lastname: Lee
mesh_terms: D060433:Administration, Ophthalmic; D000818:Animals; D000001:Calcimycin / Q000494:pharmacology; D061207:Calcium Ionophores / Q000494:pharmacology; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy* / Q000276:immunology*; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology*; D018836:Inflammation Mediators / Q000378:metabolism; D038143:Inula / Q000737:chemistry*; D007783:Lactones / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D008297:Male; D008407:Mast Cells / Q000378:metabolism*; D008813:Mice, Inbred ICR; D016328:NF-kappa B / Q000378:metabolism; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects* / Q000276:immunology; D010766:Phosphorylation / Q000187:drug effects; D008517:Phytotherapy; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives / Q000494:pharmacology; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D061207:Calcium Ionophores; D016207:Cytokines; D018836:Inflammation Mediators; D007783:Lactones; D016328:NF-kappa B; D012717:Sesquiterpenes; C575454:britannin; D000001:Calcimycin; C016658:phorbolol myristate acetate; D048051:p38 Mitogen-Activated Protein Kinases; D013755:Tetradecanoylphorbol Acetate
keywords: Britanin; Mast Cells; Mitogen-Activated Protein (MAP) Kinases; Nuclear Factor (NF)-κB; Passive Cutaneous Anaphylaxis (PCA); Pro-Inflammatory Cytokines